208 related articles for article (PubMed ID: 30514676)
41. The risk of developing a mismatch repair deficient colorectal cancer after undergoing cholecystectomy.
Halldorsson MO; Hauptmann M; Snaebjornsson P; Haraldsdóttir KH; Aspelund T; Gudmundsson EF; Gudnason V; Jonasson JG; Haraldsdottir S
Scand J Gastroenterol; 2018 Aug; 53(8):972-975. PubMed ID: 30010450
[TBL] [Abstract][Full Text] [Related]
42. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Chalabi M; Fanchi LF; Dijkstra KK; Van den Berg JG; Aalbers AG; Sikorska K; Lopez-Yurda M; Grootscholten C; Beets GL; Snaebjornsson P; Maas M; Mertz M; Veninga V; Bounova G; Broeks A; Beets-Tan RG; de Wijkerslooth TR; van Lent AU; Marsman HA; Nuijten E; Kok NF; Kuiper M; Verbeek WH; Kok M; Van Leerdam ME; Schumacher TN; Voest EE; Haanen JB
Nat Med; 2020 Apr; 26(4):566-576. PubMed ID: 32251400
[TBL] [Abstract][Full Text] [Related]
43. Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines.
Chang DK; Goel A; Ricciardiello L; Lee DH; Chang CL; Carethers JM; Boland CR
Cancer Lett; 2003 Jun; 195(2):243-51. PubMed ID: 12767533
[TBL] [Abstract][Full Text] [Related]
44. Preoperative contrast-enhanced CT imaging and clinicopathological characteristics analysis of mismatch repair-deficient colorectal cancer.
Chen S; Du W; Cao Y; Kong J; Wang X; Wang Y; Lu Y; Li X
Cancer Imaging; 2023 Oct; 23(1):97. PubMed ID: 37828626
[TBL] [Abstract][Full Text] [Related]
45. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.
Hassen S; Ali AA; Kilaparty SP; Al-Anbaky QA; Majeed W; Boman BM; Fields JZ; Ali N
Mol Cell Biochem; 2016 Jan; 412(1-2):297-305. PubMed ID: 26728996
[TBL] [Abstract][Full Text] [Related]
46. Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers.
Li J; Guo Y; Liu J; Guo F; Du L; Yang Y; Li X; Ma Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597851
[TBL] [Abstract][Full Text] [Related]
47. Association between local immune cell infiltration, mismatch repair status and systemic inflammatory response in colorectal cancer.
Gunnarsson U; Strigård K; Edin S; Gkekas I; Mustonen H; Kaprio T; Böckelman C; Hagström J; Palmqvist R; Haglund C
J Transl Med; 2020 Apr; 18(1):178. PubMed ID: 32316975
[TBL] [Abstract][Full Text] [Related]
48. The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency.
Yunlong W; Tongtong L; Hua Z
Cancer Med; 2023 Feb; 12(3):2440-2452. PubMed ID: 35904113
[TBL] [Abstract][Full Text] [Related]
49. Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: A systematic review and meta-analysis.
Deng Z; Qin Y; Wang J; Wang G; Lang X; Jiang J; Xie K; Zhang W; Xu H; Shu Y; Zhang Y
Clin Genet; 2020 Jan; 97(1):25-38. PubMed ID: 31432497
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
Garrity MM; Burgart LJ; Mahoney MR; Windschitl HE; Salim M; Wiesenfeld M; Krook JE; Michalak JC; Goldberg RM; O'Connell MJ; Furth AF; Sargent DJ; Murphy LM; Hill E; Riehle DL; Meyers CH; Witzig TE;
J Clin Oncol; 2004 May; 22(9):1572-82. PubMed ID: 15117979
[TBL] [Abstract][Full Text] [Related]
51. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.
Hestetun KE; Aasebø K; Rosenlund NB; Müller Y; Dahl O; Myklebust MP
Mod Pathol; 2021 Jan; 34(1):161-170. PubMed ID: 32737450
[TBL] [Abstract][Full Text] [Related]
52. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.
Haraldsdottir S; Roth R; Pearlman R; Hampel H; Arnold CA; Frankel WL
Fam Cancer; 2016 Apr; 15(2):253-60. PubMed ID: 26666765
[TBL] [Abstract][Full Text] [Related]
53. Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients.
Liu SS; Yang YZ; Jiang C; Quan Q; Xie QK; Wang XP; He WZ; Rong YM; Chen P; Yang Q; Yang L; Zhang B; Xia XJ; Kong PF; Xia LP
J Transl Med; 2018 Jul; 16(1):195. PubMed ID: 30005666
[TBL] [Abstract][Full Text] [Related]
54. Gut microbiota distinct between colorectal cancers with deficient and proficient mismatch repair: A study of 230 CRC patients.
Jin M; Wu J; Shi L; Zhou B; Shang F; Chang X; Dong X; Deng S; Liu L; Cai K; Nie X; Zhang T; Fan J; Liu H
Front Microbiol; 2022; 13():993285. PubMed ID: 36312959
[TBL] [Abstract][Full Text] [Related]
55. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
[TBL] [Abstract][Full Text] [Related]
56. miRNA expression in colon polyps provides evidence for a multihit model of colon cancer.
Oberg AL; French AJ; Sarver AL; Subramanian S; Morlan BW; Riska SM; Borralho PM; Cunningham JM; Boardman LA; Wang L; Smyrk TC; Asmann Y; Steer CJ; Thibodeau SN
PLoS One; 2011; 6(6):e20465. PubMed ID: 21694772
[TBL] [Abstract][Full Text] [Related]
57. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair.
Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS
Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048
[TBL] [Abstract][Full Text] [Related]
58. Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro.
Horvath LG; Henshall SM; Kench JG; Saunders DN; Lee CS; Golovsky D; Brenner PC; O'Neill GF; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL
Clin Cancer Res; 2004 Jan; 10(2):615-25. PubMed ID: 14760084
[TBL] [Abstract][Full Text] [Related]
59. Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study.
Pina A; Wolber R; McAlpine JN; Gilks B; Kwon JS
Int J Gynecol Cancer; 2018 Oct; 28(8):1624-1630. PubMed ID: 30095707
[TBL] [Abstract][Full Text] [Related]
60. Evidence for an Association of ERCC1 Expression and Mismatch Repair Status with Overall Survival in Colorectal Cancer Patients.
Li P; Xiao ZT; Braciak TA; Ou QJ; Chen G; Oduncu FS
Oncol Res Treat; 2017; 40(11):702-706. PubMed ID: 29065415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
